ICU Medical (NASDAQ:ICUI) Releases Earnings Results, Beats Estimates By $0.46 EPS

ICU Medical (NASDAQ:ICUI) posted its earnings results on Thursday. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $1.91 by $0.46, FiscalAI reports. The firm had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a return on equity of 7.94% and a net margin of 1.39%.ICU Medical’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.10 earnings per share. ICU Medical updated its FY 2026 guidance to 8.600-9.000 EPS.

Here are the key takeaways from ICU Medical’s conference call:

• Second-quarter results exceeded expectations on earnings momentum, with organic revenue growth of 6%, adjusted EBITDA up 10% to $110 million, and adjusted EPS up 13% to $2.37.
• ICU Medical raised and narrowed its 2026 adjusted EBITDA guidance to $415 million–$435 million and adjusted EPS guidance to $8.60–$9.00, while increasing expected full-year adjusted gross margin to approximately 41.5%.
• Infusion Systems and Consumables delivered record sales, growing 12% and 5% organically, respectively. Management expects Systems organic growth at or above 6% in the near term and continued mid-single-digit growth in Consumables.
• Strong free cash flow of $62 million, including a $20 million tariff refund, enabled $50 million of debt repayment and reduced net leverage to 2.3 times; management remains on track for approximately 2 times leverage by year-end.
• The outlook still faces pressure from tariffs, unfavorable currencies, and higher oil and diesel costs, while Vital Care declined 4% organically and is expected to remain slightly down for the full year. Some pump installations occurred earlier than expected, and the timing of Medfusion 5000 FDA resubmission and CAD development remains uncertain.

ICU Medical Stock Performance

Shares of NASDAQ ICUI traded up $18.19 during trading hours on Friday, reaching $184.56. The stock had a trading volume of 931,233 shares, compared to its average volume of 304,941. The firm has a market cap of $4.61 billion, a price-to-earnings ratio of 156.41, a PEG ratio of 2.58 and a beta of 0.74. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $192.85. The firm has a 50-day moving average of $151.64 and a 200-day moving average of $141.02.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Piper Sandler lifted their price target on ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. BTIG Research boosted their target price on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Finally, Wall Street Zen raised shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $192.80.

More ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

Insider Buying and Selling

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the sale, the vice president owned 19,460 shares in the company, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares of the company’s stock, valued at $978,363.60. The trade was a 23.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

Institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC raised its position in ICU Medical by 4.2% in the 4th quarter. Janus Henderson Group PLC now owns 2,576,756 shares of the medical instruments supplier’s stock valued at $367,625,000 after purchasing an additional 103,220 shares during the last quarter. Millennium Management LLC grew its position in ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after purchasing an additional 690,694 shares during the last quarter. State Street Corp increased its stake in ICU Medical by 2.8% in the fourth quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier’s stock valued at $134,491,000 after purchasing an additional 25,545 shares during the period. Dimensional Fund Advisors LP increased its stake in ICU Medical by 5.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 920,776 shares of the medical instruments supplier’s stock valued at $131,370,000 after purchasing an additional 47,783 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in shares of ICU Medical by 34.0% in the third quarter. Ameriprise Financial Inc. now owns 803,542 shares of the medical instruments supplier’s stock valued at $96,393,000 after buying an additional 203,746 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.